晚期乳腺癌一线内分泌治疗联合贝伐珠单抗未能获得生存获益
만기유선암일선내분비치료연합패벌주단항미능획득생존획익
Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival
  • 万方数据
    循证医学 순증의학
    THE JOURNAL OF EVIDENCE-BASED MEDICINE
    2015年 3期 141-143 ,共3页

    林颖%邵楠%任重阳

    림영%소남%임중양

    晚期乳腺癌%贝伐珠单抗%内分泌治疗%无进展生存期%总生存期 晚期乳腺癌%貝伐珠單抗%內分泌治療%無進展生存期%總生存期
    만기유선암%패벌주단항%내분비치료%무진전생존기%총생존기
    advanced breast cancer%Bevacizumab%endocrine therapy%progression-free survival%overall survival


    원문보기 원문다운로드 사이트로이동
저자의 최근 논문